株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のOTC医薬品市場予測:主要企業の見通し

World OTC Pharmaceutical Market Forecast 2016-2026: Recent M&A Activity and Prospects for Rx-to-OTC Switching in Cough, Cold and Allergy, Analgesics, Gastrointestinal Medicines and Other Leading Segments

発行 Visiongain Ltd 商品コード 320889
出版日 ページ情報 英文 247 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.80円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のOTC医薬品市場予測:主要企業の見通し World OTC Pharmaceutical Market Forecast 2016-2026: Recent M&A Activity and Prospects for Rx-to-OTC Switching in Cough, Cold and Allergy, Analgesics, Gastrointestinal Medicines and Other Leading Segments
出版日: 2016年03月01日 ページ情報: 英文 247 Pages
概要

世界のOTC医薬品市場は2016年に1,270億米ドルに達すると予測されています。

当レポートでは、世界のOTC医薬品市場について調査し、業界の成長動向、国別動向、収益予測、主要企業のプロファイルなどをまとめています。

第1章 レポートの概要

第2章 OTC医薬品のイントロダクション

  • OTC医薬品とは
  • OTC医薬品の分類
  • OTC医薬品に対する要件とは
  • OTCスイッチ
  • OTC医薬品の製造と流通
  • OTC医薬品に関する法規制
  • 市場セグメンテーション

第3章 世界のOTC医薬品市場の予測

  • 世界のOTC医薬品市場の実績
  • 世界のOTC医薬品市場売上予測
  • OTC医薬品市場セグメント

第4章 主要国市場の予測

  • 地域別内訳
  • 地域別予測
  • 変化する市場シェア:中国の台頭
  • 米国市場
  • 日本市場
  • EU5か国市場
  • 中国市場
  • ブラジル市場
  • ロシア市場
  • インド市場
  • メキシコ市場
  • その他

第5章 主要企業

  • 主要メーカー
  • GSK (Novartisとの合弁)
  • Novartis (GSKとのOTC合弁)
  • Bayer
  • Merck & Co(Bayerによりコンシューマーケア部門買収)
  • Johnson and Johnson
  • Perrigo
  • Pfizer
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi
  • Boehringer Ingelheim
  • Mylan、OTC市場に参入

第6章 OTCスイッチと将来のOTC医薬品

  • OTCスイッチとは
  • OTCスイッチ活動
  • 潜在的候補
  • 咳、風邪、アレルギー
  • 鎮痛剤
  • 胃腸薬
  • 皮膚
  • 失禁用抗コリン薬
  • 経口避妊薬
  • コレステロール抑制剤の需要の高さ
  • その他

第7章 OTC医薬品市場の定性分析

第8章 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0094

What can be expected from the Over-the-Counter Pharmaceuticals Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 247-page report provides 148 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of over-the-counter medicines market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2026? Our study forecasts revenues in the following Over-the-Counter Pharmaceuticals submarkets:

  • Analgesics
  • Cough, Cold and Allergy
  • Gastrointestinal
  • Dermatological
  • Eye Care
  • Smoking Cessation Aids
  • Other Products (grouped category).

See detailed profiles or revenue forecasts for some the leading drugs in the market

How will leading drug perform to 2026? Our study provides detailed forecasts revenues for a number of leading drugs in the over-the-counter medicine market including:

  • Voltaren
  • Bayer Aspirin

Profiles are also included for the following:

  • Panadol
  • Alli
  • Flonase Allergy Relief
  • Claritin
  • Tylenol
  • Rhinocort Allergy
  • Nicorette
  • Nexium
  • Advil
  • Prilosec OTC
  • Mucinex
  • Nasacort
  • Allegra
  • Clarinex

See revenue forecasts for the leading international markets

How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:

  • US
  • EU5 - Germany, UK, France, Italy and Spain
  • China
  • Japan
  • India
  • Russia
  • Brazil
  • Mexico

Leading companies and potential for market growth

Visiongain forecasts overall revenue for the Over-the-Counter Pharmaceuticals Market will exceed $127bn in 2016. We predict revenue growth higher than the rate of the total pharmaceutical market through to 2026. Advances in mHealth, a more liberal regulatory landscape, strong support from governments in multiple regions to meet the growing demands of an ageing increasing population and the launch of several new therapies in areas for chronic conditions will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of nine leading companies, including these:

  • GSK Consumer Health (JV with Novartis)
  • Bayer
  • Johnson and Johnson
  • Perrigo
  • Pfizer
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi
  • Boehringer Ingelheim

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the over-the-counter medicines industry?

Our new report discusses issues and events affecting the over-the-counter medicines medicine market. You will find discussions, including qualitative analyses:

  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future successful OTC switches
  • Significant company M&A activity changing the competitive landscape of the whole market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How The World OTC Pharmaceuticals Market Forecast 2016-2026 report helps you

In summary, our 247-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the OTC pharma market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading over-the-counter medicine products in the following areas: cough, cold and allergy, analgesics, gastrointestinal, dermatological, eye care, and smoking cessation aids.
  • Detailed profiles or revenue forecasts to 2026 for the leading drugs in the over-the-counter medicine market - discover prospects for leading over-the-counter brands: Voltaren, and Bayer Aspirin and profiles for Panadol, Alli, Flonase Allergy Relief, Claritin, Tylenol, Rhinocort Allergy, Nicorette, Nexium, Advil, Prilosec OTC, Mucinex, Nasacort, Allegra, Clarinex
  • Revenue forecasts to 2026 for twelve leading national market and one leading regional markets - US, EU5, China, Japan, India, Russia, Brazil, and Mexico.
  • Assessment of nine leading companies - analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the over-the-counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The OTC Pharmaceuticals Market Overview
  • 1.2 OTC Pharmaceuticals Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Introduction to OTC Pharmaceuticals

  • 2.1. What Are OTC Pharmaceuticals?
  • 2.2. Classification of OTC Pharmaceuticals
  • 2.3. What are the Requirements for an OTC Pharmaceutical Drug?
  • 2.4 OTC Switching
    • 2.4.1. How Is a Drug Switched from Prescription to OTC?
  • 2.5. Manufacturing and Distribution of OTC Pharmaceuticals
  • 2.6. Regulation of OTC Pharmaceuticals
    • 2.6.1. Regulation of OTC Pharmaceuticals in the US
    • 2.6.2. Regulation of OTC Pharmaceuticals in Japan: Deregulating the Sales of OTCs
    • 2.6.3. Regulation of OTC Pharmaceuticals in Europe
    • 2.6.4. Regulation of OTC Pharmaceuticals in China
    • 2.6.5. Regulation of OTC Pharmaceuticals in Others Countries
  • 2.7 OTC Pharmaceuticals: Market Segmentation
    • 2.7.1. Analgesics
      • 2.7.1.1. Internal Analgesics
      • 2.7.1.2. External Analgesics
    • 2.7.2. Cough, Cold and Allergy Products
      • 2.7.2.1. Cough and Cold Remedies
      • 2.7.2.2. Anti-Allergy Products
    • 2.7.3. Dermatological Products
      • 2.7.3.1. Minor Cuts and Wounds
      • 2.7.3.2. Acne
      • 2.7.3.3. Rashes, Itchy Skin, and Dermatitis/Eczema
      • 2.7.3.4. Cold Sores
      • 2.7.3.5. Warts
      • 2.7.3.6. Fungal Skin Infections
      • 2.7.3.7. Haemorrhoids
      • 2.7.3.8. Other Dermatological Products
    • 2.7.4. Gastrointestinal Products
      • 2.7.4.1. Indigestion and Heartburn
      • 2.7.4.2. Anti-Diarrhoea OTC Pharmaceuticals
      • 2.7.4.3. Laxatives
      • 2.7.4.4. Anti-Emetic OTC Pharmaceuticals
      • 2.7.4.5. Anti-Obesity OTC Pharmaceuticals
    • 2.7.5. Eye Care
      • 2.7.5.1. Dry Eye Syndrome
      • 2.7.5.2. Bacterial Conjunctivitis
      • 2.7.5.3. Ocular Allergy and Allergic Conjunctivitis
      • 2.7.5.4. Treatment of Ocular Allergy/ Allergic Conjunctivitis
    • 2.7.6. Smoking Cessation Aids
    • 2.7.7. Other OTC Products
    • 2.7.8. Vitamins, Minerals and Supplements

3. The World OTC Pharmaceutical Market 2016-2026

  • 3.1. The World OTC Pharma Market in 2014 and 2015
    • 3.1.1 OTC Pharma Market Segmentation in 2015 and 2016
    • 3.1.2. Leading OTC Pharma Brands
    • 3.1.3. Leading Companies in the OTC Market in 2014 and 2015
  • 3.2. The World OTC Pharma Market: Sales Forecast 2016-2026
    • 3.2.1. The World OTC Pharma Market, 2016-2026: Drivers and Restraints
  • 3.3 OTC Pharma Market Segments: Sales Forecasts, 2016-2026
    • 3.3.1. CAGRs by OTC Segment, 2015-2025
    • 3.3.2. Changing Market Shares by OTC Segment, 2016-2026
    • 3.3.3. Cough, Cold and Allergy OTC Market: Sales Forecast 2016-2026
    • 3.3.4. Analgesics OTC Market: Sales Forecast 2016-2026
    • 3.3.5. Gastrointestinal OTC Market: Sales Forecast 2016-2026
    • 3.3.6. Dermatological OTC Market: Sales Forecast 2016-2026
    • 3.3.7. Eye Care OTC Market: Sales Forecast 2016-2026
    • 3.3.8. Smoking Cessation OTC Market: Sales Forecast 2014-2026
    • 3.3.9. Other OTC Market: Sales Forecast 2016-2026

4. The Leading National Markets 2016-2026

  • 4.1. Regional Breakdown of the World OTC Pharma Market in 2014 and 2015
  • 4.2. The World OTC Pharmaceutical Market: Regional Forecast 2016-2026
  • 4.3. Changing Market Shares of Leading National Markets: Emerging Dominance of China
  • 4.4. The US OTC Pharmaceutical Market Sales Forecast, 2016-2026
    • 4.4.1. The US OTC Pharma Market: Financial Incentives to Using OTC Drugs
    • 4.4.2. The US OTC Pharma Market: Leading Companies
  • 4.5. The Japanese OTC Pharmaceutical Market Sales Forecast, 2015-2025
    • 4.5.1. The Japanese OTC Pharma Market: Deregulation could Stimulate Growth
    • 4.5.2. The Japanese OTC Pharma Market: Leading Companies
  • 4.6. The EU5 OTC Pharma Market in 2014 and 2015
    • 4.6.1. Changing Market Shares of the EU5 OTC Pharmaceuticals Market
    • 4.6.2. The EU5 OTC Market Sales Forecast, 2016-2026
    • 4.6.3. The EU5 OTC Pharma Market: Leading Companies
    • 4.6.4. The German OTC Pharmaceutical Market Sales Forecast, 2016-2026
    • 4.6.5. The UK OTC Pharmaceutical Market Sales Forecast, 2015-2025
      • 4.6.5.1. The UK's Liberal OTC Regulations
    • 4.6.6. The French OTC Pharmaceutical Market Sales Forecast, 2016-2026
      • 4.6.6.1 OTC Drugs: A French Monopoly System
    • 4.6.7. The Italian OTC Pharmaceutical Market Sales Forecast, 2015-2025
    • 4.6.8. The Spanish OTC Pharmaceutical Market Sales Forecast, 2016-2026
  • 4.7. The Chinese OTC Pharmaceutical Market Sales Forecast, 2016-2026
    • 4.7.1. The Chinese OTC Pharma Market: Leading Companies
    • 4.7.2. The Role of Traditional Chinese Medicines (TCM) in the Chinese OTC Market
  • 4.8. The Brazilian OTC Pharmaceutical Market Sales Forecast, 2016-2026
    • 4.8.1. The Brazilian OTC Pharma Market: An Overview
  • 4.9. The Russian OTC Pharmaceutical Market Sales Forecast, 2016-2026
    • 4.9.1. The Russian OTC Pharma Market: Overview
  • 4.10. The Indian OTC Pharmaceutical Market Sales Forecast, 2016-2026
    • 4.10.1. The Indian OTC Pharma Market: An Overview
  • 4.11. The Mexican OTC Pharmaceutical Market Sales Forecast, 2016-2026
  • 4.12. The Rest of the World OTC Pharmaceutical Market Sales Forecast, 2016-2026

5. Leading Companies in the OTC Pharma Market 2016-2026

  • 5.1. Leading OTC Pharmaceutical Manufacturers, 2015
    • 5.1.1. Leading OTC Pharmaceutical Manufacturers after completed Transactions, 2015
  • 5.2. GSK
    • 5.2.1. GSK Consumer Healthcare Unit: Historical Activity
    • 5.2.2. GSK Consumer Healthcare Formed by a Joint-Venture Undertaken by GSK and Novartis
    • 5.2.3. GSK/Novartis: Additional Transactions
    • 5.2.4. GSK Consumer Healthcare: OTC Sales Forecast, 2015-2026
    • 5.2.5. Flonase Launched in US
    • 5.2.6. Panadol
    • 5.2.7. Voltaren Gel
      • 5.2.7.1. Voltaren Gel: Sales Forecast 2015-2025
    • 5.2.8. Alli: A Beleaguered Brand
    • 5.2.9. GSK Smoking Cessation Products
  • 5.3. Novartis (OTC Joint Venture with GSK)
    • 5.3.1. Novartis: Transformational Year
  • 5.4. Bayer
    • 5.4.1. Acquisition of Merck's Consumer Care Business, 2014
    • 5.4.2. Bayer Acquires Dihon in 2014
    • 5.4.3. Bayer: OTC Sales Forecast, 2014-2025
    • 5.4.4. Bayer Aspirin
    • 5.4.5. Bayer Aspirin: Sales Forecast 2016-2026
    • 5.4.6. Claritin OTC (Loratadine)
  • 5.5. Merck & Co (Consumer Care Segment Acquired by Bayer)
  • 5.6. Johnson and Johnson
    • 5.6.1. FDA Governance of McNeil Manufacturing Activity
    • 5.6.2. Johnson & Johnson: OTC Sales Forecast, 2014-2026
    • 5.6.3. Rhinocort Allergy Spray
    • 5.6.4. Tylenol
    • 5.6.5. Nicorette
  • 5.7. Perrigo
    • 5.7.1. Perrigo: OTC Sales Forecast, 2014-2026
    • 5.7.2. Perrigo Benefits from Challenges Faced by J&J
    • 5.7.3. Perrigo: Growth by Acquisition
    • 5.7.4. Perrigo Acquires Omega Pharma
    • 5.7.5. Perrigo Acquires GSK Portfolio
    • 5.7.6. Perrigo Expands Mexican Capacity and Capabilities
    • 5.7.7. Mylan's Hostile Takeover Bid
  • 5.8. Pfizer
    • 5.8.1. Pfizer: OTC Sales Forecast, 2015-2025
    • 5.8.2. Pfizer Announces Merger with Allergan
    • 5.8.3. Pfizer Acquires Rights to AstraZeneca's OTC Nexium
    • 5.8.4. Pfizer: Bulking up Their OTC Product Portfolio
    • 5.8.5. Advil
  • 5.9. Procter & Gamble
    • 5.9.1. PGT Healthcare- Procter& Gamble's Joint Venture with Teva
    • 5.9.2. Prilosec OTC
    • 5.9.3. Major Plans for Divestment Including OTC Products
  • 5.10. Reckitt Benckiser
    • 5.10.1. Reckitt Benckiser: OTC Sales Forecast, 2014-2026
    • 5.10.2. Internal Growth by “Power” Brand Extensions: Mucinex
    • 5.10.3. Expanding Presence in Emerging Markets through Acquisition
  • 5.11. Sanofi
    • 5.11.1. Sanofi Focuses on Long-Term Growth with Potential Boehringer Ingelheim Asset Swap Pending Completion Q4 2016
    • 5.11.2. Sanofi: Acquisition of OTC Products from J&J
    • 5.11.3. Sanofi: Launch of Nasacort
    • 5.11.4. Sanofi: OTC Sales Forecast, 2014-2026
  • 5.12. Boehringer Ingelheim
    • 5.12.1. Boehringher Ingelhime: OTC Sales Forecast 2014-2026
  • 5.13. Mylan Enter OTC Market

6. OTC Switching and Potential Future of OTC Drugs

  • 6.1. OTC Switching: An Overview
    • 6.1.1. What is OTC Switching?
    • 6.1.2. Which Products Will Switch?
    • 6.1.3. How Does OTC Switching Occur?
    • 6.1.4. How Does OTC Switching Affect the OTC Pharma Market?
    • 6.1.5. Opposition to OTC Switching
  • 6.2. OTC Switching Activity, 2002-2015
    • 6.2.1. OTC Switching: Downward Trend
    • 6.2.2. The FDA NSURE Initiative: Reversing the Downward Trend in Rx-to-OTC Switches
  • 6.3. Potential Candidates for OTC Switching 2016-2026
  • 6.4. Cough, Cold and Allergy: OTC Switches
    • 6.4.1. First-Generation Antihistamines
    • 6.4.2. Allegra (fexofenadine)
    • 6.4.3. Clarinex (desloratadine)
    • 6.4.4. Rhinocort Allergy Spray (budesonide): Latest Nasal Corticosteroid Approval
    • 6.4.5. Flixotide/Flonase (fluticasone): Latest Nasal Corticosteroid Approval
    • 6.4.6. Nasacort (triamcinolone): First in Class U.S. OTC Approval
  • 6.5. Analgesics: OTC Switch Limitations
    • 6.5.1. Triptans: The U.S. Will Remain Cautious
    • 6.5.2. NSAIDs for Arthritis: Safety Concerns Incites Reverse-Switching
    • 6.5.3. Other Analgesics
  • 6.6. Gastrointestinals: OTC Switches
    • 6.6.1. H2-Receptor Blockers
    • 6.6.2. Proton Pump Inhibitors (PPIs)
      • 6.6.2.1. Omeprazole
      • 6.6.2.2. Lansoprazole
      • 6.6.2.3. Pantoprazole
      • 6.6.2.4. Esomeprazole: 2014 U.S. FDA Approval for OTC Use
      • 6.6.2.5. Rabeprazole
    • 6.6.3. Anti-Obesity Drugs
  • 6.7. Dermatologicals: OTC Switches
    • 6.7.1. Antivirals for Oral Herpes Simplex
  • 6.8. Anticholinergics for Incontinence: OTC Switches
  • 6.9. Oral Contraceptives: An OTC Switch Can have Significant Economic Benefits
  • 6.10. High Demand for OTC Cholesterol-Lowering Drugs
    • 6.10.1. Lipitor (atorvastatin): Testing Times for Pfizer
    • 6.10.2. Zocor Heart Pro (simvastatin) in the UK
    • 6.10.3 OTC Statins: U.S. Historical Setbacks
  • 6.11. Other Potential OTC Switch Categories
    • 6.11.1. High Blood Pressure: Thiaside Diuretics
    • 6.11.2. Erectile Dysfunction: Viagra (sildenafil), Cialis (tadalafil)
    • 6.11.3. Osteoporosis: (Bisphosphonates) An Undertreated Disease, but a Very Unlikely OTC Switch
    • 6.11.4. Insomnia: Silenor (doxepin)

7. Qualitative Analysis of the OTC Pharma Market, 2016-2026

  • 7.1. SWOT Analysis of the OTC Pharmaceutical Market
  • 7.2. Strengths
    • 7.2.1. Healthcare Systems, Third Party Payers, and Manufacturers: All have Incentives to Push for OTC Drug Consumption
      • 7.2.1.1. Manufacturers Can Reap OTC Sales Benefits
      • 7.2.1.2. Third Party Payers: Reducing the Cost Burden
      • 7.2.1.3. Healthcare Systems: Pushing the Cost to the Consumer
    • 7.2.2. Many Pharma Companies Have a Strong Potential OTC Portfolio
    • 7.2.3. Regulators Are Encouraging OTC Approvals
    • 7.2.4. Effective Distribution Networks Due to Expansion of Retail Pharmacy and Alternative Distributors
    • 7.2.5. Deterring the Consumption of Counterfeit Drugs
    • 7.2.6. Cultural Changes Will Support Self-Medication with OTC Medicines
  • 7.3. Weaknesses
    • 7.3.1. Pharma Companies Remain Focused on Prescription Drugs
    • 7.3.2. Manufacturing Problems Affects Sales and Reputation of OTC Drugs
    • 7.3.3 OTC Products are Vulnerable to Price Controls by Governments
    • 7.3.4. Downward Cost Pressures of OTC Drugs
  • 7.4. Opportunities
    • 7.4.1. Demographic and Economic Changes Will Create Growth Opportunities
    • 7.4.2. New OTC Switch Categories
    • 7.4.3. Strong Growth in Emerging Markets
    • 7.4.4. New Healthcare Technologies May enable OTC Approvals
    • 7.4.5. Opportunities to Drive Sales via Social Media and Online Marketing
    • 7.4.6. Self Medication can Reduce the Under Treatment of Disease
  • 7.5. Threats
    • 7.5.1. Competition from Private-Label Brands Will Reduce Profitability
    • 7.5.2. Regulatory Concerns Over Safety and Misuse may Lead to Withdrawal of Products
    • 7.5.3. Resistance to OTC Switching from Some Groups in Certain Countries
  • 7.6. Porter's Five Forces Analysis of the OTC Pharmaceutical Market
    • 7.6.1. Rivalry Among Competitors [High]
    • 7.6.2. Threat of New Entrants [Medium]
    • 7.6.3. Power of Suppliers [Low]
    • 7.6.4. Power of Buyers [Medium]
    • 7.6.5. Threats of Substitutes [Medium]

8. Conclusions

  • 8.1. The World OTC Pharma Market in 2014-2015
    • 8.1.1. The Leading OTC Product Categories
    • 8.1.2. Leading OTC Pharma Brands, 2015
    • 8.1.3. Leading OTC Manufacturers
    • 8.1.4. Leading National Markets: Emerging Market Represent a Large Proportion
    • 8.1.5. The Global OTC Market Growth Factors
    • 8.1.6. Potential OTC Switching, 2016-2026
    • 8.1.7. Emerging OTC Markets
  • 8.2. Concluding Remarks

Appendices

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1: The World OTC Pharmaceuticals Market Forecast by National Market: Revenue ($bn), AGR (%), and CAGR (%) 2014-2026
  • Table 2.1: OTC Internal Analgesic Active Ingredients, 2016
  • Table 2.2: OTC External Analgesic Active Ingredients, 2016
  • Table 2.3: OTC Cough, Cold and Allergy Active Ingredients, 2016
  • Table 2.4: OTC Antifungal Active Ingredients, 2016
  • Table 2.5: OTC Indigestion and Heartburn Active Ingredients, 2016
  • Table 2.6: OTC Anti-Diarrhoea Active Ingredients, 2016
  • Table 2.7: OTC Laxative Active Ingredients, 2016
  • Table 2.8: OTC Dry Eye Syndrome Active Ingredients, 2016
  • Table 2.9: OTC Bacterial Conjunctivitis Active Ingredients, 2016
  • Table 2.10: OTC Ocular Allergy Active Ingredients, 2016
  • Table 2.11: OTC Smoking Cessation Aid Active Ingredients, 2016
  • Table 3.1: World OTC Pharmaceutical Market Revenue by Product Category: Revenue ($bn) and Market Shares (%), 2015-2016
  • Table 3.2: Top 10 OTC Pharmaceutical Products: Revenues ($m), 2015
  • Table 3.3: Top 11 OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2014
  • Table 3.4: Top 9 OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2015
  • Table 3.5: World OTC Pharmaceuticals Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 3.6: The World OTC Pharmaceuticals Market Forecast by Product Category: Revenues ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 3.7: The World OTC Pharmaceutical Market Forecast by Product Category: CAGR (%) for 2014-2020, 2020-2026 and 2014-2026
  • Table 3.8: The World OTC Pharmaceutical Market by Product Category: Market Shares (%), 2014, 2020 and 2026
  • Table 3.9: The World OTC Pharmaceutical Market Forecast for the Cough, Cold and Allergy Market: Revenue ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 3.10: The World OTC Pharmaceutical Market Forecast for the Analgesics Market: Revenue ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 3.11: The Gastrointestinals OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2026
  • Table 3.12: The Dermatological OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2026
  • Table 3.13: The Eye Care OTC Pharma Market Forecast: Revenues ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 3.14: The Smoking Cessation Aids OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2026
  • Table 3.15: The Other Products OTC Pharma Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2026
  • Table 4.1: The World OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by Region, 2014
  • Table 4.2: The World OTC Pharmaceutical Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Region, 2014-2026
  • Table 4.3: Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2014-2020, 2020-2026 and 2014-2026
  • Table 4.4: Market Shares (%) of the Leading Regional OTC Pharmaceutical Markets, 2014, 2020 and 2026
  • Table 4.5: The US OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.6: Selected Leading Companies in the US OTC Pharma Market, 2015
  • Table 4.7: The Japanese OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.8: Selected Leading Companies in the Japanese OTC Pharma Market, 2015
  • Table 4.9: The EU5 Market: Revenue ($bn) and Market Share (%) by Region, 2014 and 2015
  • Table 4.10: The EU5 OTC Pharma Market: Market Shares (%) by National Market, 2014, 2020, 2026
  • Table 4.11: The EU5 OTC Pharma Market Forecast by Country: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.12: Selected Leading Companies in the EU5 OTC Pharma Market, 2015
  • Table 4.13: The German OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.14: The UK OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.15: The French OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.16: The Italian OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.17: The Spanish OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.18: The Chinese OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.19: Selected Leading Companies in the Chinese OTC Pharma Market, 2015
  • Table 4.20: The Brazilian OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.21: The Russian OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.22: The Indian OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.23: The Mexican OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 4.24: The Rest of the World OTC Pharma Market Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2026
  • Table 5.1: Selected Leading OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2014
  • Table 5.2: Selected OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2015
  • Table 5.3: GSK: Overview, 2015
  • Table 5.4: GSK/Novartis OTC Brands, 2015
  • Table 5.5: GSK Consumer Healthcare: OTC Sales Forecast ($Bb), AGR (%), and CAGR (%), 2015-2026
  • Table 5.6: Panadol OTC Products, 2016
  • Table 5.7: Novartis: Voltaren OTC Sales Forecast ($m), AGR (%), and CAGR (%), 2014-2026
  • Table 5.8: Nicorette OTC Products, 2015
  • Table 5.9: Bayer: Overview, 2016
  • Table 5.10: Bayer OTC Brands, 2015
  • Table 5.11: Bayer: OTC Sales Forecast ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 5.12: Bayer Aspirin: OTC Sales Forecast ($m), AGR (%), and CAGR (%), 2016-2026
  • Table 5.13: Johnson & Johnson Overview, 2016
  • Table 5.14: Johnson & Johnson OTC Brands, 2016
  • Table 5.15: Johnson & Johnson: OTC Sales Forecast ($bn), AGR (%), CAGR (%), 2014-2026
  • Table 5.16: Tylenol OTC Products, 2016
  • Table 5.17: Nicorette OTC Products, 2016
  • Table 5.18: Perrigo: Overview, 2016
  • Table 5.19: Perrigo: OTC Sales Forecast ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 5.20: Pfizer: Overview, 2016
  • Table 5.21: Pfizer OTC Brands, 2016
  • Table 5.22: Pfizer: OTC Sales Forecast ($Bn), AGR (%), and CAGR (%), 2014-2026
  • Table 5.23: Advil OTC Brands, 2016
  • Table 5.24: Procter & Gamble: Overview, 2016
  • Table 5.25: Reckitt Benckiser: Overview, 2016
  • Table 5.26: Reckitt Benckiser: OTC Sales Forecast ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 5.27: Sanofi: Overview, 2016
  • Table 5.28: Sanofi OTC Brands, 2016
  • Table 5.29: Sanofi: OTC Sales Forecast ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 5.30: Boehringer Ingelheim: Overview, 2014
  • Table 5.31: Boehringer Ingelheim OTC Brands, 2016
  • Table 5.32: Boehringer Ingelheim: OTC Sales Forecast ($bn), AGR (%), and CAGR (%), 2014-2026
  • Table 6.1: US OTC Switches by Manufacturer, 2002-March 2015
  • Table 6.2: Potential Cough, Cold and Allergy OTC Switches By Active Ingredient, 2015-2016
  • Table 6.3: Potential Analgesics OTC Switches by Active Ingredient, 2016-2026
  • Table 6.4: Potential Gastrointestinals OTC Switches By Active Ingredient, 2016-2026
  • Table 6.5: Potential Dermatologicals OTC Switches By Active Ingredient, 2016-2025
  • Table 7.1: SWOT Analysis of the OTC Pharmaceutical Market, 2016

List of Figures

  • Figure 1.1: OTC Pharmaceuticals: Overview of Submarkets
  • Figure 2.1: The OTC Pharmaceutical Supply Chain, 2016
  • Figure 3.1: World OTC Pharmaceutical Market Share(%) of the World Pharmaceutical Market, 2015
  • Figure 3.2: World OTC Pharmaceutical Market by Product Category: Market Shares(%), 2015
  • Figure 3.3: The World OTC Pharmaceuticals Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 3.4: The World OTC Pharmaceutical Market by Product Category: CAGR (%), 2014-2020
  • Figure 3.5: The World OTC Pharmaceutical Market by Product Category: CAGR (%), 2020-2026
  • Figure 3.6: The World OTC Pharmaceutical Market by Product Category: CAGR (%), 2014-2026
  • Figure 3.7: The World OTC Pharmaceutical Market by Product Category: Market Shares (%), 2020
  • Figure 3.8: The World OTC Pharmaceutical Market by Product Category: Market Shares (%), 2026
  • Figure 3.9: Comparison of the World OTC Pharmaceutical Market by Product Category: Market Shares (%), 2014 and 2026
  • Figure 3.10: The OTC Pharmaceutical Market Forecast for the Cough, Cold and Allergy Market: Revenues ($bn) and AGR (%) 2014-2026
  • Figure 3.11: The World OTC Pharmaceutical Market Forecast for the Analgesics Market: Revenues ($bn) and AGR (%) 2014-2026
  • Figure 3.12: The Gastrointestinals OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 3.13: The Dermatological OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 3.14: The Eye Care OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 3.15: The Smoking Cessation Aids OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 3.16: The Other Products OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.1: The World OTC Pharmaceutical Market: Revenues ($bn) by Region,2014
  • Figure 4.2: The World OTC Pharmaceutical Market: Market Shares (%) by Region,2014
  • Figure 4.3: Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2014-2020
  • Figure 4.4: Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2020-2026
  • Figure 4.5: Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2014-2026
  • Figure 4.6: The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2020
  • Figure 4.7: The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2026
  • Figure 4.8: The US OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.9: The Japanese OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.10: The EU5 OTC Pharmaceutical Market : Market Shares (%) by National Market, 2014
  • Figure 4.11: The EU5 OTC Pharmaceutical Market : Market Shares (%) by National Market, 2020
  • Figure 4.12: The EU5 OTC Pharmaceutical Market : Market Shares (%) by National Market, 2026
  • Figure 4.13: The EU5 OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.14: The German OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.15: The UK OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.16: The French OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.17: The Italian OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.18: The Spanish OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.19: The Chinese OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.20: The Brazilian OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.21: The Russian OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.22: The Indian OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.23: The Mexican OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 4.24: The Rest of the World OTC Pharma Market Forecast: Revenues ($bn) and AGR (%), 2014-2026
  • Figure 5.1: Selected Leading OTC Pharmaceutical Manufacturers by Market Share (%), 2014
  • Figure 5.2: Selected OTC Pharmaceutical Manufacturers by Market Share (%), 2015
  • Figure 5.3: GSK Consumer Healthcare: OTC Sales Forecast ($m), and AGR (%), 2015-2026
  • Figure 5.4: Novartis: Voltaren OTC Sales Forecast ($m), and AGR (%), 2014-2026
  • Figure 5.5: Bayer: OTC Sales Forecast ($bn), and AGR (%), 2014-2026
  • Figure 5.6: Bayer Aspirin: OTC Sales Forecast ($m), and AGR (%), 2014-2026
  • Figure 5.7: Johnson & Johnson: OTC Sales Forecast ($bn), AGR (%),2014-2026
  • Figure 5.8: Perrigo: OTC Sales Forecast ($bn), and AGR (%), 2014-2026
  • Figure 5.9: Pfizer: OTC Sales Forecast ($bn), AGR (%), 2014-2026
  • Figure 5.10: Reckitt Benckiser: OTC Sales Forecast ($Bn), and AGR (%), 2014-2026
  • Figure 5.11: Sanofi: OTC Sales Forecast ($bn), and AGR (%), 2014-2026
  • Figure 5.12: Boehringer Ingelheim: OTC Sales Forecast ($bn), AGR (%), 2014-2026
  • Figure 6.1: Number of FDA-Approved OTC Switches, By Year, 1976-2014
  • Figure 6.2: Number of FDA-Approved OTC Switches, By 5-Year Periods, 1976-2014
  • Figure 7.1: Porter's Five Analysis of the OTC Pharmaceutical Market , 2016
  • Figure 8.1: The World OTC Pharmaceutical Market: Market Share (%) by Region, 2014
  • Figure 8.2: The World OTC Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026

Companies Listed

  • Abbott Medical Optics
  • Aché Laboratórios Farmacêuticos
  • Actavis
  • Adams Respiratory Therapeutics
  • Akorn
  • Alcon
  • Allergan
  • Alliance Boots
  • Almirall
  • Amerisource Bergen
  • ANVISA
  • Apotex
  • Arena Pharmaceuticals
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo
  • B.F. Ascher & Company
  • Bausch & Lomb
  • Bayer
  • Boehringer Ingelheim
  • Boots
  • Bristol-Myers Squibb
  • Cardinal Health
  • Celesio
  • China Resources Sanjiu Pharmaceutical
  • Ciba
  • Cilag
  • Cipla
  • Costco
  • CSPC (China Shijiazhuang Pharmaceutical Group)
  • CVS
  • Daiichi Sankyo
  • Dalkhimpharm
  • Dollar General
  • Dr. Reddy's Laboratories
  • Eisai
  • Eli Lilly
  • EMS
  • Eurofarma
  • Fosun Pharma
  • Galderma
  • Genomma Lab
  • GSK
  • Guangzhou Pharmaceutical
  • Harbin Pharmaceutical Group
  • Heritage/Insight
  • Hisamitsu
  • Hypermacas
  • Insight
  • Ipca Laboratories
  • JB Chemicals
  • Johnson & Johnson
  • Kangmei Pharmaceutical
  • Kowa
  • Kroger
  • Lion
  • LOréal
  • Lupin Limited
  • Mankind Pharma
  • McKesson
  • Menarini
  • Merck
  • Mylan
  • North China Pharmaceutical
  • Novartis
  • Nycomed
  • Omega Pharma
  • Otsuka
  • Paras Pharmaceuticals
  • Perrigo
  • Pfizer
  • Pharmstandard
  • Phoenix
  • Prestige Brands
  • Procter & Gamble
  • Purdue Pharma
  • Ranbaxy
  • Ratiopharm
  • Reckitt Benckiser
  • Roche
  • Rohto
  • Roxane Labs
  • Sam's Club
  • Sandoz
  • Sanofi
  • Sato
  • Sergeant
  • Shanghai Pharmaceuticals
  • Shionogi
  • Sinopharm
  • SkyePharma
  • Somaxon Pharmaceuticals
  • Sotex
  • SSL International
  • Stada
  • Sun Pharma
  • Taisho
  • Takeda
  • Teva
  • Torrent Pharmaceuticals
  • Typharm
  • UCB Pharma
  • União Química
  • Valeant
  • Velcera
  • Veropharm
  • Vivus

Other Organisations Mentioned in This Report

  • Association of the European Self-Medication Industry (AESGP)
  • National Pharmaceutical Pricing Authority (NPPA)
  • The Brazilian Health Surveillance Agency
  • The European Medicines Agency (EMA)
  • The Food and Drug Administration (FDA)
  • The General Directorate of Pharmaceuticals and Pharmacy (IEGM) (Turkey)
  • The Medicines and Healthcare products Regulatory Agency (MHRA)
  • The Ministry of Health, Labour and Welfare (MHLW)
  • The Pharmaceutical and Medical Devices Agency (PMDA)
Back to Top